Global Brain Tumor Therapeutics Market 2021-2025

Global Brain Tumor Therapeutics Market 2021-2025

Technavio has been monitoring the brain tumor therapeutics market and it is poised to grow by $ 1.23 billion during 2021-2025, progressing at a CAGR of 9.67% during the forecast period. Our report on the brain tumor therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of brain cancer and strategic alliances. In addition, the increasing prevalence of brain cancer is anticipated to boost the growth of the market as well.

The brain tumor therapeutics market analysis includes the type segment and geographic landscape.

Technavio's brain tumor therapeutics market is segmented as below:

By Type

• Small molecules
• Biologics

By Geographic

• North America
• Europe
• Asia
• ROW

This study identifies the high morbidity of brain tumorsas one of the prime reasons driving the brain tumor therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on brain tumor therapeutics market covers the following areas:

• Brain tumor therapeutics market sizing
• Brain tumor therapeutics market forecast
• Brain tumor therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading brain tumor therapeutics market vendors that include Amgen Inc., Bristol-Myers Squibb Co., Eisai Co. Ltd., Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., NextSource Pharmaceuticals LLC, Novartis AG, and Y-mAbs Therapeutics Inc. Also, the brain tumor therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

Amgen Inc., Bristol-Myers Squibb Co., Eisai Co. Ltd., Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., NextSource Pharmaceuticals LLC, Novartis AG, Y-mAbs Therapeutics Inc.